المؤلفون: Dersch R; Clinic of Neurology and Neurophysiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Torbahn G; Department of Pediatrics, Paracelsus Medical University, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität Nürnberg, Nuremberg, Germany., Rauer S; Clinic of Neurology and Neurophysiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

المصدر: European journal of neurology [Eur J Neurol] 2024 Jul; Vol. 31 (7), pp. e16293. Date of Electronic Publication: 2024 Apr 12.

نوع المنشور: Systematic Review; Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1331 (Electronic) Linking ISSN: 13515101 NLM ISO Abbreviation: Eur J Neurol Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/drug therapy , Lyme Disease*/complications, Humans ; Post-Lyme Disease Syndrome/drug therapy ; Post-Lyme Disease Syndrome/therapy ; Anti-Bacterial Agents/therapeutic use ; Quality of Life ; Randomized Controlled Trials as Topic ; Depression/etiology ; Depression/drug therapy

مستخلص: Background and Purpose: Residual symptoms after treatment of Lyme disease, sometimes called post-treatment Lyme disease symptoms (PTLDs), are a matter of ongoing controversy. To guide treatment recommendations, a systematic review was performed of the available literature on specific treatment for PTLDs.
Methods: A systematic literature search of MEDLINE and CENTRAL was performed. No restrictions on case definitions, study types or specific interventions were applied to enable a comprehensive overview of the available literature. Risk of bias was assessed using the Cochrane risk of bias tools for randomized controlled trials. Certainty of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach. Outcomes of interest were quality of life, fatigue, depression and cognition as well as adverse events.
Results: After screening 1274 records, eight eligible randomized controlled trials were included. Heterogeneity was observed regarding inclusion criteria, intervention, length of treatment and outcome measures. For efficacy outcomes, results are presented narratively due to heterogeneity. Eligible studies show no statistically significant difference between antibiotics and placebo regarding quality of life, cognition and depression. Results for fatigue were inconsistent whilst studies with low risk of bias showed no statistically significant difference between antibiotics and placebo. Meta-analysis of safety outcomes showed statistically significantly more adverse events for antibiotics compared to placebo.
Conclusions: Available literature on treatment of PTLDs is heterogeneous, but overall shows evidence of no effect of antibiotics regarding quality of life, depression, cognition and fatigue whilst showing more adverse events. Patients with suspected PTLDs should not be treated with antibiotics.
(© 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)

المؤلفون: Derderian GP; Michigan Vascular Institute, Birmingham, Michigan, USA., Otenbaker N; Michigan Vascular Institute, Birmingham, Michigan, USA.

المصدر: Journal of cosmetic dermatology [J Cosmet Dermatol] 2024 Jun; Vol. 23 (6), pp. 2044-2048. Date of Electronic Publication: 2024 Apr 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Blackwell Science Country of Publication: England NLM ID: 101130964 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-2165 (Electronic) Linking ISSN: 14732130 NLM ISO Abbreviation: J Cosmet Dermatol Subsets: MEDLINE

مواضيع طبية MeSH: Quality of Life* , Post-Lyme Disease Syndrome*/therapy , Post-Lyme Disease Syndrome*/diagnosis, Humans ; Prospective Studies ; Female ; Middle Aged ; Male ; Adult ; Lyme Disease/complications ; Lyme Disease/drug therapy ; Lyme Disease/diagnosis ; Lyme Disease/therapy ; Treatment Outcome ; Magnetic Field Therapy/methods ; Magnetic Field Therapy/instrumentation ; Aged

مستخلص: Background: We previously demonstrated a possible therapeutic benefit of VFEM (variable frequency electromagnetic energy) technology for the treatment of Post Treatment Lyme Disease Syndrome (PTLDS) or Chronic Lyme Disease (CLD). As a result, we prospectively enrolled 10 patients, all having significant debility, to determine to what extent we could improve their quality of life. Eight patients completed the 10 treatments.
Results: All eight patients had a significant improvement in quality of life within a 4-month time frame.
Conclusion: VFEM is a stand-alone modality that appears to demonstrate a significant improvement in quality of life in PTLDS or CLD with little or no risk or side effects of treatment.
(© 2024 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.)

المؤلفون: Stark JH; Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Cambridge, Massachusetts, USA., McFadden B; Behavioralize LLC, Wynnewood, Pennsylvania, USA.; The Department of Agricultural Economics and Agribusiness, University of Arkansas, Fayetteville, Arkansas, USA., Patel N; Behavioralize LLC, Wynnewood, Pennsylvania, USA., Kelly PH; Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, Pennsylvania, USA., Gould LH; Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, New York, New York, USA., Riis J; Behavioralize LLC, Wynnewood, Pennsylvania, USA.

المصدر: Zoonoses and public health [Zoonoses Public Health] 2024 Jun; Vol. 71 (4), pp. 349-358. Date of Electronic Publication: 2024 Jan 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Blackwell Verlag Country of Publication: Germany NLM ID: 101300786 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1863-2378 (Electronic) Linking ISSN: 18631959 NLM ISO Abbreviation: Zoonoses Public Health Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/prevention & control , Intention*, Humans ; Adult ; Female ; Male ; United States ; Health Belief Model ; Vaccination/psychology ; Middle Aged ; Health Knowledge, Attitudes, Practice ; Lyme Disease Vaccines ; Young Adult ; Adolescent

مستخلص: Aims: Lyme disease (LD) cases in the United States are estimated to be approaching 500,000 annually. Protective measures, such as repellent use and wearing protective clothing are recommended by public health officials. However, no protective measure has been proven to be consistently effective, partly because they require consistent and persistent behaviour change. While safe and effective vaccines are in development, it is unclear what factors influence the intention to vaccinate against LD. This study uses the Health Belief Model (HBM) framework to determine key drivers associated with vaccine intention. The HBM is widely applied in public health research and uses the following constructs: perceived susceptibility and severity of disease, perceived benefits and barriers to disease prevention, and cues to action for disease prevention to predict health behaviours. To date, the HBM framework has not been applied to vaccination intention for LD.
Methods and Results: Data were collected from 874 adults and 834 caregivers of children residing in US states endemic to LD. Sampling adults and caregivers allows us to explore how the intention to vaccinate differs among those at-risk. Estimates from structural equation modelling (SEM) show that the HBM constructs explain much of the variation in intention to vaccinate against LD. Both adult and caregiver intentions to vaccinate are positively influenced by cues to action, perceived susceptibility of LD, and perceived benefits to vaccination. However, there is variation in the influence of constructs across the samples. Caregiver's intention to vaccinate is positively influenced by the perceived severity of LD and negatively influenced by safety concerns about the vaccine, whereas adult intention is negatively influenced by perceived barriers to vaccination.
Conclusion: A strong relationship of cues to action on vaccine intention in samples of adults and caregivers suggests the importance of a recommendation from a healthcare provider or the Centers for Disease Control and Prevention (CDC).
(© 2024 Pfizer Inc. Zoonoses and Public Health published by Wiley‐VCH GmbH.)

المؤلفون: Pavia CS; Department of Biomedical Sciences, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, NY, United States.; Division of Infectious Diseases, New York Medical College, Valhalla, NY, United States., Saggio G; Department of Clinical Specialties, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, NY, United States., Plummer MM; Department of Clinical Specialties, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, NY, United States.

المصدر: Frontiers in immunology [Front Immunol] 2024 Feb 14; Vol. 14, pp. 1326623. Date of Electronic Publication: 2024 Feb 14 (Print Publication: 2023).

نوع المنشور: Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/epidemiology , Lyme Disease*/prevention & control , Borrelia burgdorferi* , Borrelia burgdorferi Group*, United States ; Humans ; Lyme Disease Vaccines ; Antibodies, Bacterial

مستخلص: Working together, two major pharmaceutical companies have developed a Lyme disease vaccine consisting of recombinant-derived outer surface protein A (OspA) of the etiologic agent Borrelia burgdorferi . Multiple clinical trials have shown the vaccine to have good safety and efficacy results, and it is hoped that it would become available for human use at least by the year 2025 after receiving approval from the U.S. Food and Drug Administration. There are still challenges left to ensure that the vaccine has, at most, minimal side effects. Also, because the previously developed Lyme disease vaccine was discontinued in 2002 after four years of distribution, due in part, for frivolous reasons having little or no scientific basis, that even led to legal entanglements involving the vaccine manufacturer and some of the medical personnel overseeing the clinical trials, there will be concerns that this newly developed one could be subject again to some of the same unnecessary scrutiny rendering its implementation suboptimal. Initially this review will focus on the key epidemiological, microbiologic, immunologic and clinical aspects of Lyme disease that provide the foundation for developing this type of vaccine that could have a serious impact on the prevalence of this and even certain other tick-transmitted infections.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Pavia, Saggio and Plummer.)

المؤلفون: Vance DJ; Division of Infectious Diseases, New York State Department of Health, Wadsworth Center, Albany, New York, USA.; Department of Biomedical Sciences, University at Albany, Albany, New York, USA., Basir S; Department of Biomedical Sciences, University at Albany, Albany, New York, USA., Piazza CL; Division of Infectious Diseases, New York State Department of Health, Wadsworth Center, Albany, New York, USA., Willsey GG; Division of Infectious Diseases, New York State Department of Health, Wadsworth Center, Albany, New York, USA., Haque HME; Department of Chemistry, The University of Kansas, Lawrence, Kansas, USA., Tremblay JM; Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts, USA., Rudolph MJ; New York Structural Biology Center, New York, New York, USA., Muriuki B; Department of Medicine, University of Massachusetts Chan School of Medicine, Worcester, Massachusetts, USA., Cavacini L; Department of Medicine, University of Massachusetts Chan School of Medicine, Worcester, Massachusetts, USA., Weis DD; Department of Chemistry, The University of Kansas, Lawrence, Kansas, USA., Shoemaker CB; Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts, USA., Mantis NJ; Division of Infectious Diseases, New York State Department of Health, Wadsworth Center, Albany, New York, USA.; Department of Biomedical Sciences, University at Albany, Albany, New York, USA.

المصدر: Infection and immunity [Infect Immun] 2024 Apr 09; Vol. 92 (4), pp. e0008424. Date of Electronic Publication: 2024 Mar 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society For Microbiology Country of Publication: United States NLM ID: 0246127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-5522 (Electronic) Linking ISSN: 00199567 NLM ISO Abbreviation: Infect Immun Subsets: MEDLINE

مواضيع طبية MeSH: Single-Domain Antibodies* , Lyme Disease*/prevention & control , Lipoproteins*, Animals ; Dogs ; Humans ; Lyme Disease Vaccines ; Epitopes ; Antibodies, Bacterial ; Bacterial Vaccines ; Bacterial Outer Membrane Proteins ; Antigens, Surface ; Antibodies, Monoclonal

مستخلص: Camelid-derived, single-domain antibodies (V H Hs) have proven to be extremely powerful tools in defining the antigenic landscape of immunologically heterogeneous surface proteins. In this report, we generated a phage-displayed V H H library directed against the candidate Lyme disease vaccine antigen, outer surface protein A (OspA). Two alpacas were immunized with recombinant OspA serotype 1 from Borrelia burgdorferi sensu stricto strain B31, in combination with the canine vaccine RECOMBITEK Lyme containing lipidated OspA. The phage library was subjected to two rounds of affinity enrichment ("panning") against recombinant OspA, yielding 21 unique V H Hs within two epitope bins, as determined through competition enzyme linked immunosorbent assays (ELISAs) with a panel of OspA-specific human monoclonal antibodies. Epitope refinement was conducted by hydrogen exchange-mass spectrometry. Six of the monovalent V H Hs were expressed as human IgG1-Fc fusion proteins and shown to have functional properties associated with protective human monoclonal antibodies, including B. burgdorferi agglutination, outer membrane damage, and complement-dependent borreliacidal activity. The V H Hs displayed unique reactivity profiles with the seven OspA serotypes associated with B. burgdorferi genospecies in the United States and Europe consistent with there being unique epitopes across OspA serotypes that should be considered when designing and evaluating multivalent Lyme disease vaccines.
Competing Interests: The authors declare no conflict of interest.

المؤلفون: Gidengil C; RAND Corporation, 20 Park Plaza, Suite 910, Boston, MA 02116, USA. Electronic address: gidengil@rand.org., Scherer AM; University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA., Parker AM; RAND Corporation, 4570 Fifth Ave #600, Pittsburgh, PA 15213, USA., Gedlinske A; University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA., Fleck-Derderian S; Centers for Disease Control and Prevention, National Centers for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, 3156 Rampart Road, Fort Collins, CO 80521, USA., Hinckley AF; Centers for Disease Control and Prevention, National Centers for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, 3156 Rampart Road, Fort Collins, CO 80521, USA., Hook SA; Centers for Disease Control and Prevention, National Centers for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, 3156 Rampart Road, Fort Collins, CO 80521, USA., Lindley MC; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Immunization Services Division, 1600 Clifton Road, Atlanta, GA 30329, USA., Marx GE; Centers for Disease Control and Prevention, National Centers for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, 3156 Rampart Road, Fort Collins, CO 80521, USA.

المصدر: Vaccine [Vaccine] 2024 Mar 19; Vol. 42 (8), pp. 1899-1905. Date of Electronic Publication: 2024 Feb 28.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE

مواضيع طبية MeSH: Vaccines* , Lyme Disease*/prevention & control, Child ; Humans ; United States ; Lyme Disease Vaccines ; Intention ; Health Knowledge, Attitudes, Practice ; Parents ; Antibodies, Monoclonal ; Vaccination

مستخلص: Background: Lyme disease (LD) is the most common vector-borne disease in the United States, with increasing incidence and geographic range. Case incidence peaks among school-aged children. New LD preventives are in clinical trials.
Methods: We conducted an online survey of parents of children aged 5-18 years in states with high or emerging incidence of LD. Our primary outcome was willingness ("definitely" or "probably") for their child to receive an LD vaccine. Our secondary outcome was preference for annual monoclonal antibody injections compared to a 3-dose vaccine series with boosters. Analyses were weighted to reflect parent gender, parent race/ethnicity, and child age by state.
Results: Among 1,351 parent respondents, most (68.0 %) would have their child vaccinated against LD, with significantly more being willing in high compared to emerging incidence states (70.4 % versus 63.6 %, p = 0.027). Of parents who were unsure or unwilling, 33.5 % and 16.5 %, respectively, would do so with a provider recommendation. Vaccine safety concerns were among the top reasons for LD vaccine hesitancy. More parents preferred a pre-formed antibody (42.3 %) compared to a 3-dose vaccine series (34.7 %). Significant predictors of willingness to have one's child vaccinated were higher parental education; higher perceived risk of child getting LD; child spending time outdoors daily or weekly; following a regular vaccine schedule; and positive attitude towards vaccines. Significant predictors of preference for monoclonal antibody over a 3-dose vaccine series included prior awareness of LD, living in a rural area, and less positive attitudes towards vaccines.
Conclusions: Two-thirds of parents in high and emerging incidence states would vaccinate their children against Lyme disease. Addressing safety concerns will be important, and a health care provider recommendation could also encourage those who are unsure or unwilling. Given the slight preference for monoclonal antibody over vaccine, particularly in rural areas, access to both may increase LD prevention.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Courtney Gidengil reports financial support was provided by Centers for Disease Control and Prevention. I have served as an ad hoc reviewer for manuscripts submitted to Vaccine in the past. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 RAND Corporation. Published by Elsevier Ltd.. All rights reserved.)

المؤلفون: Chen YL; Department of Pediatrics, Division of Tropical Medicine, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA., Lee J; Department of Pediatrics, Division of Tropical Medicine, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA., Liu Z; Department of Pediatrics, Division of Tropical Medicine, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA., Strych U; Department of Pediatrics, Division of Tropical Medicine, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA., Bottazzi ME; Department of Pediatrics, Division of Tropical Medicine, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA; Department of Biology, Baylor University, Waco, TX, USA., Lin YP; Division of Infectious Diseases, Wadsworth Center, NYSDOH, Albany, NY, USA; Department of Biomedical Sciences, SUNY Albany, Albany, NY, USA. Electronic address: Yi-Pin.Lin@tufts.edu., Chen WH; Department of Pediatrics, Division of Tropical Medicine, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA. Electronic address: Wen-Hsiang.Chen@bcm.edu.

المصدر: International journal of biological macromolecules [Int J Biol Macromol] 2024 Feb; Vol. 259 (Pt 2), pp. 129295. Date of Electronic Publication: 2024 Jan 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7909578 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0003 (Electronic) Linking ISSN: 01418130 NLM ISO Abbreviation: Int J Biol Macromol Subsets: MEDLINE

مواضيع طبية MeSH: Borrelia burgdorferi* , Lyme Disease*/prevention & control, Humans ; Lyme Disease Vaccines ; Escherichia coli/genetics ; Seroepidemiologic Studies ; Bacterial Outer Membrane Proteins/chemistry

مستخلص: Lyme disease, caused by Lyme Borrelia spirochetes, is the most common vector-borne illness in the United States. Despite its global significance, with an estimated 14.5 % seroprevalence, there is currently no licensed vaccine. Previously, we demonstrated that CspZ-YA protein conferred protection against Lyme Borrelia infection, making it a promising vaccine candidate. However, such a protein was tagged with hexahistidine, and thus not preferred for vaccine development; furthermore, the formulation to stabilize the protein was understudied. In this work, we developed a two-step purification process for tag-free E. coli-expressed recombinant CspZ-YA. We further utilized various bioassays to analyze the protein and determine the suitable buffer system for long-term storage and formulation as a vaccine immunogen. The results indicated that a buffer with a pH between 6.5 and 8.5 stabilized CspZ-YA by reducing its surface hydrophobicity and colloidal interactions. Additionally, low pH values induced a change in local spatial conformation and resulted in a decrease in α-helix content. Lastly, an optimal salinity of 22-400 mM at pH 7.5 was found to be important for its stability. Collectively, this study provides a fundamental biochemical and biophysical understanding and insights into the ideal stabilizing conditions to produce CspZ-YA recombinant protein for use in vaccine formulation and development.
Competing Interests: Declaration of competing interest JL, ZL, US, MEB, and WHC are co-inventors and/or patent holders of several vaccine technologies against neglected tropical and/or other emerging diseases owned by Baylor College of Medicine (BCM); nothing to report. YPL is the Co-inventor and patent holder for CspZ-YA molecules (patent number US20220280627A1) owned by the New York State Department of Health (NYSDH). All authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or material discussed in the manuscript.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)

المؤلفون: Rudolph MJ; New York Structural Biology Center, New York, New York, USA., Davis SA; New York Structural Biology Center, New York, New York, USA., Haque HME; Department of Chemistry, University of Kansas, Lawrence, Kansas, USA., Ejemel M; MassBiologics, University of Massachussetts Chan Medical School, Boston, Massachusetts, USA., Cavacini LA; MassBiologics, University of Massachussetts Chan Medical School, Boston, Massachusetts, USA., Vance DJ; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA., Willsey GG; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA., Piazza CL; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA., Weis DD; Department of Chemistry, University of Kansas, Lawrence, Kansas, USA., Wang Y; MassBiologics, University of Massachussetts Chan Medical School, Boston, Massachusetts, USA., Mantis NJ; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA.

المصدر: Proteins [Proteins] 2023 Nov; Vol. 91 (11), pp. 1463-1470. Date of Electronic Publication: 2023 Jul 16.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8700181 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0134 (Electronic) Linking ISSN: 08873585 NLM ISO Abbreviation: Proteins Subsets: MEDLINE

مواضيع طبية MeSH: Bacterial Outer Membrane Proteins*/chemistry , Bacterial Outer Membrane Proteins*/immunology , Lipoproteins*/chemistry , Lipoproteins*/immunology , Borrelia burgdorferi*/immunology , Borrelia burgdorferi*/chemistry , Lyme Disease*/immunology , Antibodies, Monoclonal*/immunology , Antibodies, Monoclonal*/chemistry , Antigens, Surface*/immunology , Antigens, Surface*/chemistry , Antibodies, Bacterial*/immunology , Antibodies, Bacterial*/chemistry , Bacterial Vaccines*, Crystallography, X-Ray ; Humans ; Animals ; Immunoglobulin Fab Fragments/chemistry ; Immunoglobulin Fab Fragments/immunology ; Models, Molecular ; Mice ; Lyme Disease Vaccines/immunology ; Lyme Disease Vaccines/chemistry ; Protein Binding

مستخلص: 319-44 is a human monoclonal antibody capable of passively protecting mice against tick-mediated infection with Borreliella burgdorferi, the bacterial genospecies responsible for Lyme disease in North America. In vitro, 319-44 has complement-dependent borreliacidal activity and spirochete agglutinating properties. Here, we report the 2.2 Å-resolution crystal structure of 319-44 Fab fragments in complex with Outer surface protein A (OspA), the ~30 kDa lipoprotein that was the basis of the first-generation Lyme disease vaccine approved in the United States. The 319-44 epitope is focused on OspA β-strands 19, 20, and 21, and the loops between β-strands 16-17, 18-19, and 20-21. Contact with loop 20-21 explains competition with LA-2, the murine monoclonal antibody used to estimate serum borreliacidal activities in the first-generation Lyme disease vaccine clinical trials. A high-resolution B-cell epitope map of OspA will accelerate structure-based design of second generation OspA-based vaccines.
(© 2023 Wiley Periodicals LLC.)

المؤلفون: Courville JM; Department of Obstetrics and Gynecology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada., Czuzoj-Shulman N; Center for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Quebec, Canada., Spence AR; Center for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Quebec, Canada., Abenhaim HA; Department of Obstetrics and Gynecology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.; Center for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Quebec, Canada.

المصدر: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics [Int J Gynaecol Obstet] 2024 Jul; Vol. 166 (1), pp. 451-457. Date of Electronic Publication: 2024 Jan 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0210174 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3479 (Electronic) Linking ISSN: 00207292 NLM ISO Abbreviation: Int J Gynaecol Obstet Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/epidemiology , Pregnancy Complications, Infectious*/epidemiology , Pregnancy Outcome*/epidemiology, Humans ; Female ; Pregnancy ; Adult ; Retrospective Studies ; Infant, Newborn ; United States/epidemiology ; Incidence ; Young Adult ; Abruptio Placentae/epidemiology ; Premature Birth/epidemiology

مستخلص: Objective: The incidence of Lyme disease (LD) infections has risen in recent decades. Gestational LD has been associated with adverse pregnancy outcomes; however, the results have been contradictory. The study objective was to examine the effects of gestational LD on obstetrical and neonatal outcomes.
Methods: Using the Healthcare Cost & Utilization Project National (Nationwide) Inpatient Sample from the United States, we conducted a retrospective cohort study of pregnant patients admitted to the hospital between 2016 and 2019. The exposed group consisted of pregnant patients with gestational LD infection (International Classification of Diseases, Tenth Revision [ICD-10] code A692x), while the comparison group consisted of pregnant patients without gestational LD. Descriptive statistics and multivariate logistic regression models, adjusted for baseline maternal characteristics, were used to determine the associations between gestational LD and obstetrical and neonatal outcomes.
Results: The cohort included 2 943 575 women, 226 of whom were diagnosed with LD during pregnancy. The incidence of LD was 7.67 per 100 000 pregnancy admissions. The incidence of gestational LD was stable over the study period. Pregnant patients with LD were more likely white, older, to have private health insurance, and to belong to a higher income quartile. Gestational LD was associated with an increased risk of placental abruption (adjusted odds ratio [aOR], 3.45 [95% confidence interval (CI), 1.53-7.80]) and preterm birth (aOR, 1.58 [95% CI, 1.03-2.42]).
Conclusion: Gestational LD is associated with a higher risk of placental abruption and preterm birth. Pregnancies complicated by LD, while associated with a higher risk of certain adverse outcomes, can be followed in most healthcare settings.
(© 2024 International Federation of Gynecology and Obstetrics.)

المؤلفون: Donovan A; Royal College of Surgeons in Ireland, Dublin, Ireland., Quilty R; The Hospital for Sick Children, Toronto, Ontario, Canada., Joy BK; Dalhousie University, Halifax, Nova Scotia, Canada., Seddigh S; Division of Orthopedic Surgery, Nova Scotia Health, Halifax, Canada., Coatsworth H; National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, Manitoba, Canada., Gauthier L; Division of Orthopedic Surgery, IWK Health, Halifax, Nova Scotia, Canada., Comeau JL; Division of Pediatric Infectious Diseases, IWK Health, Halifax, Nova Scotia, Canada., Lang B; Division of Pediatric Rheumatology, IWK Health, Halifax, Nova Scotia, Canada., Leblanc J; Department of Pathology and Laboratory Medicine, Nova Scotia Health, Halifax, Canada., Hatchette T; Department of Pathology and Laboratory Medicine, Nova Scotia Health, Halifax, Canada., Stringer E; Division of Pediatric Rheumatology, IWK Health, Halifax, Nova Scotia, Canada.

المصدر: Microbiology spectrum [Microbiol Spectr] 2024 Jun 04; Vol. 12 (6), pp. e0359323. Date of Electronic Publication: 2024 Apr 29.

نوع المنشور: Journal Article; Validation Study

بيانات الدورية: Publisher: ASM Press Country of Publication: United States NLM ID: 101634614 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2165-0497 (Electronic) Linking ISSN: 21650497 NLM ISO Abbreviation: Microbiol Spectr Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/diagnosis , Lyme Disease*/blood , Antibodies, Bacterial*/blood , Borrelia burgdorferi*/immunology , Arthritis, Infectious*/diagnosis , Arthritis, Infectious*/microbiology , Sensitivity and Specificity* , Immunoglobulin G*/blood, Humans ; Child ; Retrospective Studies ; Male ; Female ; Adolescent ; Child, Preschool ; Diagnosis, Differential ; Immunoglobulin M/blood ; Serologic Tests/methods

مستخلص: Lyme arthritis can present similarly to other causes of joint pain and swelling including septic arthritis and other acute and chronic arthropathies of childhood. Septic arthritis, although rare, constitutes an orthopedic emergency and requires early surgical intervention to reduce the risk of permanent joint damage. Currently, results of standard serologic tests to diagnose Lyme disease take days to weeks, which is unhelpful in acute clinical decision-making. Thus, some children with Lyme arthritis are treated empirically for septic arthritis undergoing unnecessary invasive procedures and hospital admission while on inappropriate antibiotic therapy. We retrospectively validated the Quidel Sofia Lyme Fluorescent Immunoassay, a rapid serologic assay that can detect IgG and/or IgM antibodies to Borrelia burgdorferi in 10 minutes, in residual serum samples collected from 51 children who had Lyme arthritis and 55 children with musculoskeletal presentations who were Lyme negative. The sensitivity and specificity of the Sofia IgG to identify cases of Lyme arthritis in children were 100% (95% confidence interval [CI] of 93.0%-100%) and 96.4% (95% CI: 87.5%-99.6%), respectively. The positive likelihood ratio (LR) was 27.5 (95% CI 7-107), and the negative LR was 0.00 (95% LR 0.00-0.15). We propose that the Sofia IgG, a rapid method for identifying Lyme arthritis, may be useful in differentiating Lyme arthritis from other forms of arthritis. Used in conjunction with readily available clinical and laboratory variables, it could help to rapidly identify children who are at low risk of septic arthritis in Lyme-endemic regions.
Importance: Lyme arthritis is a common manifestation of Lyme disease in children, with clinical features overlapping with other causes of acute and chronic joint pain/swelling in children. We have demonstrated that the Sofia IgG is a reliable test to rule in and rule out the diagnosis of Lyme arthritis in children with musculoskeletal presentations in a Lyme-endemic region. When used in conjunction with clinical and laboratory variables routinely considered when differentiating Lyme arthritis from other diagnoses, the Sofia IgG has the potential to fill an important gap in care, especially when acute decision-making is necessary. The Sofia IgG should be included in prospective research studies examining clinical prediction tools to identify children at low risk of septic arthritis.
Competing Interests: The authors declare no conflict of interest.